secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2023-08-31T23:59:59+00:00
Accession:  0001558370-23-015390
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune receives Nasdaq deficiency notice for ADS bid price below $1.00; 180-day cure period ends Feb 27, 2024
--------------------------------------------------------------------------------

- Received Nasdaq notice on Aug 31, 2023 for non-compliance with minimum bid price of $1.00 per ADS for 30 consecutive business days.
- Has 180 calendar days, until February 27, 2024, to regain compliance by closing at $1.00 for ten consecutive business days.
- If not compliant by Feb 27, may transfer to Nasdaq Capital Market for additional 180-day period subject to other standards.
- Company intends to monitor bid price and assess actions; no immediate effect on listing or trading.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000155837023015390/0001558370-23-015390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000155837023015390/adap-20230831x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer